Skip to main content
Clinical Trials/NCT07281794
NCT07281794
Recruiting
Not Applicable

Clinical Validity of the DANU Sports System for Gait and Balance Assessment in Parkinson's Disease

Northumbria University2 sites in 1 country60 target enrollmentStarted: August 8, 2025Last updated:

Overview

Phase
Not Applicable
Status
Recruiting
Enrollment
60
Locations
2
Primary Endpoint
Stride Length

Overview

Brief Summary

This observational study aims to explore the use of the DANU Smart Socks for gait and balance assessment in people with Parkinson's (PwP). The study will compare walking and balance outcomes produced by DANU from people with Parkinson's (PwP) and a group of healthy individuals of similar age. The project aims to investigate if the gait and balance data collected are linked to measures of Parkinson's symptoms such as disease progression and cognitive abilities. Gait and balance outcomes will be obtained through one observational laboratory visit.

Detailed Description

Methods:

Institutional ethics have been obtained (Project ID: 8543). Utilising an observational design, participants will be asked to attend one visit to Northumbria University, Newcastle Upon Tyne.

Visit 1: Participants will complete a series of clinical and cognitive measures including the Movement Disorders Society's-Unified Parkinson's Disease Rating Scale, Montreal Cognitive Assessment, Freezing of Gait Questionnaire and Falls Efficacy Scale to act as descriptive measures. Following this, the investigators will conduct a concurrent data collection throughout a battery of motor tasks. The DANU system will be used alongside APDM Mobility Lab throughout the full duration of data collection. Mobility assessments include a 2-Minute Walk Test, 3 walkway trials, a Timed Up and Go and a series of 2-Minute Balance tasks.

Study Design

Study Type
Observational
Observational Model
Case Control
Time Perspective
Cross Sectional

Eligibility Criteria

Ages
50 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Parkinson's Group Inclusion Criteria:- Clinical diagnosis of Parkinson's by a movement disorder specialist according to UK brain bank criteria.
  • PD stages I-III (Hoehn and Yahr Rating Scale)
  • Able to attend Northumbria University, Newcastle Upon Tyne for study visits.
  • Able to walk and stand unassisted for a minimum of 2-minutes.
  • Aged 50 years old or over
  • Parkinson's Group

Exclusion Criteria

  • History of neurological disorders other than PD (e.g., Huntington's disease, stroke, traumatic brain injury, multiple sclerosis, Alzheimer's disease etc.)
  • Unable to walk or stand unaided.
  • Montreal Cognitive Assessment (MoCA) score \< 21
  • Significant issues unrelated to PD that may affect gait (e.g., musculoskeletal issues, back pain, recent surgery etc.)
  • Healthy Control Inclusion Criteria:
  • Ability to attend Northumbria University, Newcastle Upon Tyne for study visits.
  • Aged 50 years old or over.
  • Able to walk and stand unassisted for a minimum of 2-minutes.
  • Healthy Control Exclusion Criteria:
  • History of neurological disorders (e.g. Huntington's disease, stroke, traumatic brain injury, multiple sclerosis, Alzheimer's disease etc.)

Arms & Interventions

Healthy Control (HC)

Aged-matched (over 50 years old) healthy controls who meet the described eligibility criteria will be recruited to participate in this study. The aim is to recruit 60 participants.

Parkinson's Disease (PD)

Participants with a clinical diagnosis of Parkinson's Disease meeting the described eligibility criteria will be recruited to take part within this study. The aim is to recruit 60 people with Parkinson's.

Outcomes

Primary Outcomes

Stride Length

Time Frame: Outcomes will be obtained in one visit (Day 1).

(m, mean ± standard deviation)

Step Time

Time Frame: Outcomes will be obtained in one visit (Day 1).

(s, mean ± standard deviation)

Stride Time

Time Frame: Outcomes will be obtained in one visit (Day 1).

(s, mean ± standard deviation)

Cadence

Time Frame: Outcomes will be obtained in one visit (Day 1).

(steps per minute, mean ± standard deviation)

Ground Contact Time

Time Frame: Outcomes will be obtained in one visit (Day 1).

(s, mean ± standard deviation)

Swing Time

Time Frame: Outcomes will be obtained in one visit (Day 1).

(s, mean ± standard deviation)

Stride Velocity

Time Frame: Outcomes will be obtained in one visit (Day 1).

(m/s, mean ± standard deviation)

Gait Velocity

Time Frame: Outcomes will be obtained in one visit (Day 1).

(m/s, mean ± standard deviation)

Area of Ellipse

Time Frame: Outcomes will be obtained in one visit (Day 1).

(mm², mean ± standard deviation)

Length of Ellipse

Time Frame: Outcomes will be obtained in one visit (Day 1).

(mm, mean ± standard deviation)

Width of Ellipse

Time Frame: Outcomes will be obtained in one visit (Day 1).

(mm, mean ± standard deviation)

Total Displacement

Time Frame: Outcomes will be obtained in one visit (Day 1).

(mm, mean ± standard deviation)

Medio-Lateral Range

Time Frame: Outcomes will be obtained in one visit (Day 1).

(mm, mean ± standard deviation)

Anterior-Posterior Range

Time Frame: Outcomes will be obtained in one visit (Day 1).

(mm, mean ± standard deviation)

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

GabriellaGatti

Postgraduate Research Student

Northumbria University

Study Sites (2)

Loading locations...

Similar Trials